New strategies for NSCLC: Is inhibition of tumour vasculature useful?;Neue Strategien beim NSCLC: Was bringt die Hemmung der Tumorgefä ße

Pneumologie

Volumn 64, Issue 6, 2010, Pages 376-386

  Reinmuth, N ^a   Steins, M ^a   Kreuter, M ^a   Thomas, M ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; AE 941; AFLIBERCEPT; ANGIOGENESIS INHIBITOR; AXITINIB; BEVACIZUMAB; BIBF 1120; CARBOPLATIN; CEDIRANIB; CISPLATIN; ENDOSTATIN; GEMCITABINE; IMATINIB; IMC 1121B; MONOCLONAL ANTIBODY DC101; MOTESANIB; PACLITAXEL; PEGAPTANIB; PLACEBO; RANIBIZUMAB; SEMAXANIB; SORAFENIB; SU 11657; SUNITINIB; THROMBOSPONDIN 1; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VASCULAR TARGETING AGENT; VASCULOTROPIN INHIBITOR; VATALANIB; XL 647; ZD 2171; ZK 22258; ANTINEOPLASTIC AGENT; COMBRETASTATIN A4 PHOSPHATE; STILBENE DERIVATIVE;

ADVANCED CANCER; CLINICAL TRIAL; HUMAN; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; REVIEW; TUMOR VASCULARIZATION; CARCINOMA, NON-SMALL-CELL LUNG; CELL DEATH; DRUG APPROVAL; DRUG DELIVERY SYSTEM; DRUG EFFECTS; LUNG NEOPLASMS; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CELL DEATH; DRUG APPROVAL; DRUG DELIVERY SYSTEMS; HUMANS; LUNG NEOPLASMS; STILBENES;

EID: 77953674705     PISSN: 09348387     EISSN: 14388790     Source Type: Journal    
DOI: 10.1055/s-0029-1243974     Document Type: Review

References (104)

1. Thomas M, Rube C, Hoffknecht P et al. Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer. Lancet Oncol 2008; 9: 636- 648
2. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997; 111: 1710-1717
3. Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin 1999; 49: 33-64, 31
4. Souhami RL, Law K. Longevity in small cell lung cancer. A report to the Lung Cancer Subcommittee of the United Kingdom Coordinating Committee for Cancer Research. Br J Cancer 1990; 61: 584-589
5. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70
6. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-1186
7. Reinmuth N, Stoeltzing O, Liu W et al. Endothelial survival factors as targets for antineoplastic therapy. Cancer J 2001; 7 Suppl 3: S109- S119
8. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005; 23: 1011-1027
9. Korff T, Kimmina S, Martiny-Baron G, Augustin HG. Blood vessel maturation in a 3-dimensional spheroidal coculture model: direct contact with smooth muscle cells regulates endothelial cell quiescence and abrogates VEGF responsiveness. FASEB J 2001; 15: 447-457
10. Yano S, Nishioka Y, Goto H, Sone S. Molecular mechanisms of angiogenesis in non-small cell lung cancer, and therapeutics targeting related molecules. Cancer Sci 2003; 94: 479-485
11. Dome B, Timar J, Dobos J et al. Identification and clinical significance of circulating endothelial progenitor cells in human non-small cell lung cancer. Cancer Res 2006; 66: 7341-7347
12. Mancuso P, Burlini A, Pruneri G et al. Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood 2001; 97: 3658-3661
13. Holash J, Maisonpierre PC, Compton D et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999; 284: 1994-1998
14. Reinmuth N, Piegelbrock E, Raedel M et al. Prognostic significance of vessel architecture and vascular stability in non-small cell lung cancer. Lung Cancer 2007; 55: 53-60
15. Mandarino LJ, Sundarraj N, Finlayson J, Hassell HR. Regulation of fibronectin and laminin synthesis by retinal capillary endothelial cells and pericytes in vitro. Exp Eye Res 1993; 57: 609-621
16. Cleaver O, Melton D A. Endothelial signaling during development. Nat Med 2003 9 661-668
17. Reinmuth N, Liersch R, Raedel M et al. Combined anti-PDGFRalpha and PDGFRbeta targeting in non-small cell lung cancer. Int J Cancer 2009 124 1535-1544
18. Eberhard A, Kahlert S, Goede V et al. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res 2000 60 1388-1393
19. Carmeliet P, Jain R K. Angiogenesis in cancer and other diseases. Nature 2000 407 249-257
20. Folkman J. Angiogenesis. Annu Rev Med 2006 57 1-18
21. Chaplin D J., Dougherty G J. Tumour vasculature as a target for cancer therapy. Br J Cancer 1999 80 Suppl 1 57-64
22. Mueller M M., Fusenig N E. Friends or foes - bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 2004 4 839-849
23. Paez-Ribes M, Allen E, Hudock J et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009 15 220-231
24. Ferrara N, Gerber H P., LeCouter J. The biology of VEGF and its receptors. Nat Med 2003 9 669-676
25. Ma J, Waxman D J. Combination of antiangiogenesis with chemotherapy for more effective cancer treatment. Mol Cancer Ther 2008 7 3670-3684
26. Fontanini G, Vignati S, Boldrini L et al. Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma. Clin Cancer Res 1997 3 861-865
27. Reck M, Pawel J von, Zatloukal P et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009 27 1227-1234
28. Sandler A, Gray R, Perry M C. et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006 355 2542-2550
29. Jain R K., Booth M F. What brings pericytes to tumor vessels? J Clin Invest 2003 112 1134-1136
30. Ebos J M., Lee C R., Kerbel R S. Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy. Clin Cancer Res 2009 15 5020-5025
31. Shaked Y, Ciarrocchi A, Franco M et al. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 2006 313 1785-1787
32. Casanovas O, Hicklin D J., Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005 8 299-309
33. Donnem T, Al-Shibli K, Al-Saad S, Busund L T., Bremnes R M. Prognostic impact of fibroblast growth factor 2 in non-small cell lung cancer: coexpression with VEGFR-3 and PDGF-B predicts poor survival. J Thorac Oncol 2009 4 578-585
34. Johnson D H., Fehrenbacher L, Novotny W F. et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004 22 2184-2191
35. Socinski M A., Langer C J., Huang J E. et al. Safety of Bevacizumab in Patients With Non-Small-Cell Lung Cancer and Brain Metastases. J Clin Oncol 2009 27 5255-5261
36. Rohr U P., Augustus S, Lasserre S F., Compton P, Huang J. Safety of bevacizumab in patients with metastases to the central nervous system. J Clin Oncol 2009 27 a2007
37. Ramalingam S S., Dahlberg S E., Langer C J. et al. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol 2008 26 60-65
38. Leighl N B., Zatloukal P, Mezger J et al. Efficacy and safety of first-line bevacizumab (Bv) and cisplatin/gemcitabine (CG) in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC) in the BO17704 study (AVAiL). J Clin Oncol 2009 27 a8050
39. Hilberg F, Roth G J., Krssak M et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 2008 68 4774-4782
40. Wilhelm S M., Carter C, Tang L et al. BAY 439006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004 64 7099-7109
41. Schiller J H., Lee J W., Hanna N H., Traynor A M., Carbone D P. A randomized discontinuation phase II study of sorafenib versus placebo in patients with non-small cell lung cancer who have failed at least two prior chemotherapy regimens: E2501. J Clin Oncol 2008 26 a8014
42. Scagliotti G, Pawel J von, Reck M et al. Phase III trial comparing carboplatin and paclitaxel with or without sorafenib in chemonaive patients with stage IIIB (with effusion) or IV non-small cell lung cancer. In, 1st IASLC-ESMO European Lung Cancer Conference. Geneva (Switzerland) 2008
43. Horn L, Sandler A. Epidermal growth factor receptor inhibitors and antiangiogenic agents for the treatment of non-small cell lung cancer. Clin Cancer Res 2009 15 5040-5048
44. Mendel D B., Laird A D., Xin X et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003 9 327-337
45. Socinski M A., Novello S, Brahmer J R. et al. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 2008 26 650-656
46. Brahmer J R., Govindan R, Novello S et al. Efficacy and safety of continuous daily sunitinib dosing in previously treated advanced non-small cell lung cancer (NSCLC): Results from a phase II study. J Clin Oncol 2007 25 a7542
47. Reck M, Frickhofen N, Gatzemeier U et al. A phase I dose escalation study of sunitinib in combination with gemcitabine + cisplatin for advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2007 25 a18057
48. Wedge S R., Ogilvie D J., Dukes M et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002 62 4645-4655
49. Ciardiello F, Bianco R, Caputo R et al. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clin Cancer Res 2004 10 784-793
50. Santoro M, Melillo R M., Carlomagno F, Fusco A, Vecchio G. Molecular mechanisms of RET activation in human cancer. Ann N Y Acad Sci 2002 963 116-121
51. Kiura K, Nakagawa K, Shinkai T et al. A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer. J Thorac Oncol 2008 3 386-393
52. Natale R B., Bodkin D, Govindan R et al. Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study. J Clin Oncol 2009 27 2523-2529
53. Heymach J V., Johnson B E., Prager D et al. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J Clin Oncol 2007 25 4270-4277
54. Heymach J V., Paz-Ares L, De Braud F et al. Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 2008 26 5407-5415
55. Herbst R S., Sun Y, Korfee S et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC). J Clin Oncol 2009 27 cra8003
56. DeBoer R, Arrieta, Gottfried M et al. Vandetanib plus pemetrexed versus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZEAL). J Clin Oncol 2009 27 a8010
57. Natale R B., Thongprasert S, Greco F A. et al. Vandetanib versus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) after failure of at least one prior cytotoxic chemotherapy: A randomized, double-blind phase III trial (ZEST). J Clin Oncol 2009 27 a8009
58. Sennino B, Falcon B L., McCauley D et al. Sequential loss of tumor vessel pericytes and endothelial cells after inhibition of platelet-derived growth factor B by selective aptamer AX102. Cancer Res 2007 67 7358-7367
59. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003 111 1287-1295
60. Pawel J von, Kaiser R, Eschbach C et al. A double blind phase II study of BIBF 1,120 in patients suffering from relapsed advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2007 25 a7635
61. Gatzemeier U, Blumenschein G, Fosella F et al. Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma. J Clin Oncol 2006 24 a7002
62. Hanna N, Ellis P, Stopfer P, Shapiro D, Gyorffy S. A Phase I study of continuous oral treatment with the triple angiokinase inhibitor BIBF 1120 together with pemetrexed in previously treated patients with non-small cell lung cancer: P3091. J Thoracic Oncol 2007 2 S717
63. Mross K B., Gmehling D, Frost A et al. A clinical Phase I, pharmacokinetic (PK), and pharmacodynamic study of twice daily BIBF 1120 in advanced cancer patients. J Clin Oncol 2005 23 a3031
64. Tozer G M., Kanthou C, Baguley B C. Disrupting tumour blood vessels. Nat Rev Cancer 2005 5 423-435
65. Blakey D C., Westwood F R., Walker M et al. Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin Cancer Res 2002 8 1974-1983
66. Lyden D, Hattori K, Dias S et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 2001 7 1194-1201
67. Siemann D W., Shi W. Dual targeting of tumor vasculature: combining Avastin and vascular disrupting agents (CA4P or OXi4503). Anticancer Res 2008 28 2027-2031
68. Dark G G., Hill S A., Prise V E. et al. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 1997 57 1829-1834
69. Hinnen P, Eskens F A. Vascular disrupting agents in clinical development. Br J Cancer 2007 96 1159-1165
70. Bilenker J H., Flaherty K T., Rosen M et al. Phase I trial of combretastatin a-4 phosphate with carboplatin. Clin Cancer Res 2005 11 1527-1533
71. Zwi L J., Baguley B C., Gavin J B., Wilson W R. Correlation between immune and vascular activities of xanthenone acetic acid antitumor agents. Oncol Res 1994 6 79-85
72. McKeage M J., Pawel J von, Reck M et al. Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Br J Cancer 2008 99 2006-2012
73. Jain R K., Duda D G., Sorensen A G. Emerging Paradigms and Potential Biomarkers of Response and Resistance in Antiangiogenic Therapy of Cancer. Educational Book ASCO 2009 716-721
74. Dowlati A, Gray R, Sandler A B., Schiller J H., Johnson D H. Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab an Eastern Cooperative Oncology Group Study. Clin Cancer Res 2008 14 1407-1412
75. Leighl N, Reck M, de Haas S et al. Analysis of biomarkers (BMs) in the AVAiL phase III randomised study of first-line Bevacizumab (Bv) with cisplatin-gemcitabine (CG) in patients (pts) with non-small cell lung cancer (NSCLC). Eur J Cancer 2009 Suppl, Vol. 7 558
76. Vermeulen P B., Gasparini G, Fox S B. et al. Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur J Cancer 2002 38 1564-1579
77. Mandrekar S J., Sargent D J. Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. J Clin Oncol 2009 27 4027-4034
78. Reinmuth N, Thomas M, Meister M, Schnabel P A., Kreuter M. Current data on predictive markers for anti-angiogenic therapy in thoracic cancers. submitted to Eur Res J
79. Cai W, Chen X. Multimodality molecular imaging of tumor angiogenesis. J Nucl Med 2008 49 Suppl 2 113S-128S
80. Ellis L M., Hicklin D J. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 2008 8 579-591
81. Shaked Y, Henke E, Roodhart J M. et al. Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 2008 14 263-273
82. Martinelli M, Bonezzi K, Riccardi E et al. Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel. Br J Cancer 2007 97 888-894
83. Reinmuth N, Bischoff H, Kindermann M, Steins M, Thomas M. Vascular Disrupting Agents beim nicht-kleinzelligen Lungenkarzinom. Atemwegs- und Lungenkrankheiten 2009 35 471-478
84. Laurie S A., Gauthier I, Arnold A et al. Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institute of Canada clinical trials group. J Clin Oncol 2008 26 1871-1878
85. Heymach J, Paz-Ares L, De Braud F et al. Randomized phase II study of vandetanib (VAN) alone or in combination with carboplatin and paclitaxel (CP) as first-line treatment for advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2007 25 a7544
86. Rizvi N A., Kris M G., Miller V A. et al. Activity of XL647 in clinically selected NSCLC patients (pts) enriched for the presence of EGFR mutations: Results from Phase 2. J Clin Oncol 2008 26 a8053
87. Schiller J H., Larson T, Ou S H. et al. Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study. J Clin Oncol 2009 27 3836-3841
88. Schiller J H., Flaherty K T., Redlinger M et al. Sorafenib combined with carboplatin/paclitaxel for advanced non-small cell lung cancer: A phase I subset analysis. J Clin Oncol 2006 24 a7194
89. Latreille J, Batist G, Laberge F et al. Phase I/II trial of the safety and efficacy of AE-941 (Neovastat) in the treatment of non-small-cell lung cancer. Clin Lung Cancer 2003 4 231-236
90. Miller V A., Wakelee H A., Lara P N. et al. Activity and tolerance of XL647 in NSCLC patients with acquired resistance to EGFR-TKIs: Preliminary results of a phase II trial. J Clin Oncol 2008 26 a8028
91. Stewart D J., Jonker D J., Goel R et al. Final clinical and pharmacokinetic (PK) results from a phase 1 study of the novel N-cadherin (N-cad) antagonist, Exherin (ADH-1), in patients with refractory solid tumors stratified according to N-cad expression. J Clin Oncol 2006 24 a3016
92. Sessa C, Perotti A, Maur M et al. An enriched phase I, pharmacokinetic and pharmacodynamic study of the N-cadherin (NCAD) cyclic competitive binder exherin (ADH-1) in patients with solid tumors. J Clin Oncol 2006 24 a3042
93. Tolcher A W., Forero L, Celio P et al. Phase I, pharmacokinetic, and DCE-MRI correlative study of AVE8062A, an antivascular combretastatin analogue, administered weekly for 3 weeks every 28-days. J Clin Oncol 2003 22 a834
94. Rustin G J., Galbraith S M., Anderson H et al. Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol 2003 21 2815-2822 (Pubitemid 46621828)
95. Stevenson J P., Rosen M, Sun W et al. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol 2003 21 4428-4438
96. Dowlati A, Robertson K, Cooney M et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 2002 62 3408-3416
97. Cooney M M., Radivoyevitch T, Dowlati A et al. Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancer. Clin Cancer Res 2004 10 96-100
98. Rustin G J., Bradley C, Galbraith S et al. 5,6-dimethylxanthenone-4- acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study. Br J Cancer 2003 88 1160-1167
99. Jameson M B., Thompson P I., Baguley B C. et al. Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent. Br J Cancer 2003 88 1844-1850
100. de Jonge M J., van der Gaast A, Planting A S. et al. Phase I and pharmacokinetic study of the dolastatin 10 analogue TZT-1027, given on days 1 and 8 of a 3-week cycle in patients with advanced solid tumors. Clin Cancer Res 2005 11 3806-3813
101. Greystoke A, Blagden S, Thomas A L. et al. A phase I study of intravenous TZT-1027 administered on day 1 and day 8 of a three-weekly cycle in combination with carboplatin given on day 1 alone in patients with advanced solid tumours. Ann Oncol 2006 17 1313-1319
102. Schoffski P, Thate B, Beutel G et al. Phase I and pharmacokinetic study of TZT-1027, a novel synthetic dolastatin 10 derivative, administered as a 1-hour intravenous infusion every 3 weeks in patients with advanced refractory cancer. Ann Oncol 2004 15 671-679
103. Beerepoot L V., Radema S A., Witteveen E O. et al. Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors. J Clin Oncol 2006 24 1491-1498
104. Gadgeel S M., LoRusso P M., Wozniak A J., Wheeler C. A dose-escalation study of the novel vascular-targeting agent, ZD6126, in patients with solid tumors. J Clin Oncol 2002 21 a438